1. Home
  2. JFR vs CAPR Comparison

JFR vs CAPR Comparison

Compare JFR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.18

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.78

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
CAPR
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
JFR
CAPR
Price
$7.18
$28.78
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
1.1M
1.2M
Earning Date
01-01-0001
03-12-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$35.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.12
$4.30
52 Week High
$8.59
$40.37

Technical Indicators

Market Signals
Indicator
JFR
CAPR
Relative Strength Index (RSI) 26.27 49.29
Support Level N/A $25.33
Resistance Level $7.97 $30.06
Average True Range (ATR) 0.07 2.13
MACD -0.01 -0.39
Stochastic Oscillator 0.00 7.67

Price Performance

Historical Comparison
JFR
CAPR

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: